Measles 2025: Trends, Prevention & Latest Updates
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- The SELECT trial followed participants for an average of 3.4 years.
- This study directly impacts the millions of individuals with obesity and pre-existing cardiovascular disease who are considering or currently using semaglutide for weight loss.
ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically significant, though modest, increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data Breakdown
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of participants receiving semaglutide versus 5.8% in the placebo group. This translates to a hazard ratio of 1.13, indicating a 13% increased risk. Importantly, the trial population consisted of adults with a body mass index (BMI) of 27 or higher and established cardiovascular disease, such as prior heart attack or stroke. The study did *not* include individuals with type 2 diabetes, focusing solely on the effects of semaglutide in those with obesity and cardiovascular risk factors.
| outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death | 1.5 | 1.2 | 1.26 |
| Nonfatal Myocardial Infarction | 3.7 | 3.1 | 1.19 |
| Nonfatal Stroke | 1.2 | 0.8 | 1.54 |
| Composite Outcome (CV Death, MI, Stroke) | 6.5 | 5.8 | 1.13 |
Who is Affected and Why This Matters
This study directly impacts the millions of individuals with obesity and pre-existing cardiovascular disease who are considering or currently using semaglutide for weight loss. Previously, semaglutide was often viewed as a relatively safe option, even perhaps offering cardiovascular benefits. The SELECT trial challenges this perception, suggesting a need for careful patient selection and monitoring. The findings also have implications for healthcare providers, who must now weigh the potential benefits of weight loss against the increased cardiovascular risk when prescribing semaglutide to this specific patient population.
Understanding the Mechanisms: Why the Increased Risk?
The precise reasons for the increased cardiovascular risk are not yet fully understood